Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced positive top-line results from the three-month, open-label second stage of the company’s multicenter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE